Comparer des méthodes

	EORTC QLQ-C30	Test d'évaluation de la BPCO
Domaine	Résultats de santé	Résultats de santé
Famille	Process / pipeline	Process / pipeline
Année d'origine	1993	2009
Auteur d'origine	Nico Aaronson et al.	Paul W. Jones et al.
Type	Self-report quality of life questionnaire	Self-report symptom and impact questionnaire
Source fondatrice	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Kline Leidy, N. (2009). Development and first validation of the COPD Assessment Test. European Respiratory Journal, 34(3), 648-654.
Alias	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	CAT, COPD Assessment Test, COPD Assessment Tool
Apparentées	5	4
Résumé	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The COPD Assessment Test (CAT) is a simple, rapid, patient-centered measure of COPD symptom burden and functional impact. Developed by Paul Jones and colleagues in 2009, this 8-item questionnaire captures how COPD affects cough, sputum, chest tightness, breathing difficulty, activity limitation, confidence, sleep, and energy. It is used worldwide in clinical practice to guide disease management decisions and as a primary outcome measure in COPD clinical trials.